Study of DSP-0390 in Patients with Recurrent High-Grade Glioma
This is a study of DSP-0390 in patients with recurrent high grade glioma.
High Grade Glioma|Glioblastoma Multiforme
DRUG: DSP-0390
Dose Escalation: Assess safety of DSP-0390 by Incidence of TEAEs and SAEs in adult patients with recurrent high-grade glioma, Occurrence of DLTs by Incidence of TEAEs and SAEs, as assessed by NCI CTCAE v5.0, From date of treatment through 30 days after End of Treatment an average of 6 months|Dose Escalation: Assess safety of DSP-0390 by severity of TEAEs and SAEs in adult patients with recurrent high-grade glioma, Occurrence of DLTs by severity of TEAEs and SAEs, as assessed by NCI CTCAE v5.0, From date of treatment through 30 days after End of Treatment an average of 6 months|Dose Escalation: Determine the MTD and/or RDE of DSP-0390, Incidence of dose-limiting toxicities, From date of first treatment through Cycle 1 (28-day cycle) DLT monitoring period|Dose Expansion: Evaluate the change in Baseline tumor activity of DSP-0390 using radiologic assessments., Evaluate the change in baseline tumor activity of DSP-0390 using radiologic assessments evaluated by RANO 2010 Evaluation Criteria, From date of first treatment, assessed by radiologic examination performed at 8-week intervals through study completion, an average of 6 months|Dose Expansion: Evaluate the safety of the Recommended Phase 2 Dose of DSP-0390 by assessment of incidence of TEAEs and SAEs, Assess the safety of the Recommended Phase 2 Dose of DSP-0390 by assessment of incidence of TEAEs and SAEs, From date of first treatment through study completion, an average of 6 months|Dose Expansion: Evaluate the safety of the Recommended Phase 2 Dose by assessment of severity of TEAEs and SAEs, Assess the safety of the Recommended Phase 2 Dose of DSP-0390 by assessment of severity of TEAEs and SAEs, From date of first treatment through study completion, an average of 6 months|Assess safety of DSP-0390 by Incidence of SAEs in adult patients with recurrent high-grade glioma consented under Protocol Amendment 5, Incidence of SAEs, as assessed by NCI CTCAE v5.0, From date of treatment through 30 days after End of Treatment an average of 12 months|Assess safety of DSP-0390 by Incidence of AEs resulting in study discontinuation in adult patients with recurrent high-grade glioma consented under Protocol Amendment 5, Incidence of AEs resulting in study discontinuation, as assessed by NCI CTCAE v5.0, From date of treatment through 30 days after End of Treatment an average of 12 months
Dose Escalation: Characterize the PK profile for AUC, PK assessed for AUC, Cycle 1 Day 1 and Cycle 2 Day 1- 0, 30 min, and 1, 2, 4, 6, 8, 10, 12 hrs, each cycle is 28 days|Dose Escalation: Characterize the PK profile for Cmax, PK assessed for Cmax, Cycle 1 Day 1 and Cycle 2 Day 1 -0, 30 min, and 1, 2, 4, 6, 8, 10, 12 hrs , each cycle is 28 days|Dose Escalation: Characterize the PK profile for tmax, PK assessed for tmax, Cycle 1 Day 1 and Cycle 2 Day 1- 0, 30 min, and 1, 2, 4, 6, 8, 10, 12 hrs , each cycle is 28 days|Dose Escalation: Characterize the PK profile for t1/2, PK assessed for t1/2, From date of first treatment, Cycle 1 Day 1 and Cycle 2 Day 1- 0, 30 min, and 1, 2, 4, 6, 8, 10, 12 hrs , each cycle is 28 days]|Dose Escalation: Characterize the PK profile for Racc, PK assessed for Racc, Cycle 1 Day 8, 15 and 22 and Cycle 2 Day 1, each cycle is 28 days|Dose Escalation: Evaluate preliminary antitumor activity, Objective response (complete or partial response) and duration of response assessed by RANO criteria., From date of first treatment, assessed by radiologic examination performed at 8-week intervals through study completion, an average of 6 months]
Exploratory: Assess the PD effect of DSP-0390, Biomarker (lathosterol/zymostenol ratio) in blood, From first date of treatment, blood tests performed at 8 week intervals through study completion, an average of 6 months
This study will evaluate the safety and efficacy of DSP-0390 in patients with recurrent high grade glioma.